X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (13) 13
index medicus (11) 11
multiple myeloma (11) 11
oncology (10) 10
hematology, oncology and palliative medicine (7) 7
multiple myeloma - drug therapy (7) 7
aged (5) 5
care and treatment (5) 5
female (5) 5
bortezomib (4) 4
dexamethasone (4) 4
hematology (4) 4
male (4) 4
middle aged (4) 4
adult (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
cancer (3) 3
chemotherapy (3) 3
clinical trials (3) 3
follow-up studies (3) 3
hemic and lymphatic diseases (3) 3
multiple myeloma - diagnosis (3) 3
multiple myeloma - mortality (3) 3
multiple myeloma - pathology (3) 3
peripheral neuropathy (3) 3
proteins (3) 3
stem-cell transplantation (3) 3
survival rate (3) 3
thalidomide (3) 3
toxicity (3) 3
transplants & implants (3) 3
analysis (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
bone marrow (2) 2
cell cycle (2) 2
consensus (2) 2
data processing (2) 2
dexamethasone - administration & dosage (2) 2
diagnosis (2) 2
disease-free survival (2) 2
dose-response relationship, drug (2) 2
enzymes (2) 2
induction (2) 2
internal medicine (2) 2
medicine (2) 2
medicine & public health (2) 2
melphalan (2) 2
metabolism (2) 2
motivation (2) 2
multiparameter flow-cytometry (2) 2
multiple myeloma - genetics (2) 2
multiple myeloma - therapy (2) 2
neoplasm recurrence, local - drug therapy (2) 2
neoplasm staging (2) 2
odds ratio (2) 2
peripheral nervous system diseases - chemically induced (2) 2
plasma cells (2) 2
positron-emission-tomography (2) 2
prognosis (2) 2
safety (2) 2
salvage therapy (2) 2
studies (2) 2
survival (2) 2
thalidomide - adverse effects (2) 2
thalidomide - analogs & derivatives (2) 2
thalidomide - therapeutic use (2) 2
transplantation, autologous (2) 2
treatment outcome (2) 2
urine (2) 2
11q (1) 1
14q32 translocations (1) 1
abdominal aortic-aneurysm (1) 1
abridged index medicus (1) 1
adolescent (1) 1
adults (1) 1
age (1) 1
alleles (1) 1
alpha sarcoglycan (1) 1
amplification (1) 1
anemia (1) 1
anemia - chemically induced (1) 1
antigens (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents, alkylating - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols (1) 1
aortic aneurysm, abdominal - genetics (1) 1
aortic aneurysm, abdominal - metabolism (1) 1
apoptosis (1) 1
arginase (1) 1
arginine (1) 1
arginine - deficiency (1) 1
arthritis, rheumatoid - drug therapy (1) 1
arthritis, rheumatoid - genetics (1) 1
arthritis, rheumatoid - metabolism (1) 1
articles (1) 1
aufsatzsammlung (1) 1
aurora a kinase (1) 1
autografts (1) 1
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. e328 - e346
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 27 - 38
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 12, pp. e538 - e548
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 11, pp. 1057 - 1065
Summary Background Bortezomib-induced peripheral neuropathy is a dose-limiting toxicity in patients with multiple myeloma, often requiring adjustment of... 
Hematology, Oncology and Palliative Medicine | APOPTOSIS | DEXAMETHASONE | EFFICACY | ONCOLOGY | REFRACTORY MYELOMA | PHASE-II | INDUCTION | STEM-CELL TRANSPLANTATION | NEUROTOXICITY | CANCER | LINES | Peripheral Nervous System Diseases - chemically induced | Prospective Studies | Humans | Middle Aged | Boronic Acids - adverse effects | Gene Expression Profiling | Young Adult | Multiple Myeloma - drug therapy | Time Factors | Antineoplastic Agents - adverse effects | Adult | Odds Ratio | Peripheral Nervous System Diseases - genetics | Genetic Predisposition to Disease | Bortezomib | Multiple Myeloma - diagnosis | Risk Assessment | Europe | Gene Frequency | Risk Factors | Treatment Outcome | Chi-Square Distribution | Adolescent | Pyrazines - adverse effects | Vincristine - adverse effects | Aged | Polymorphism, Single Nucleotide | Neoplasm Staging | Multiple Myeloma - genetics | Antimitotic agents | Care and treatment | Antineoplastic agents | Analysis | Multiple myeloma | Toxicity | Clinical trials | Nervous system | Superoxide dismutase | Single-nucleotide polymorphism | Myeloma | Peripheral neuropathy | DNA repair | Mitochondria | Coding | Cell cycle | Peripheral blood | Age | Peripheral nervous system | Enzymes | Excretion | Data processing | Inflammation | Gene expression | Metabolism | Vincristine | Quality of life | Queens | Caspase-9 | Plasma cells | Peroxisome proliferator-activated receptors | Apoptosis | Cancer
Journal Article
by Dimopoulos, Meletios A and Dimopoulos, Athanasios and Gay, Francesca and Schjesvold, Fredrik and Beksac, Meral and Hajek, Roman and Weisel, Katja Christina and Weisel, Katja and Goldschmidt, Hartmut and Maisnar, Vladimir and Moreau, Philippe and Min, Chang Ki and Pluta, Andrzej and Pluta, Agnieszka and Chng, Wee Joo and Chng, Wee-Joo and Kaiser, Martin and Zweegman, Sonja and Mateos, Maria-Victoria and Mateos, Maria Victoria and Spencer, Andrew and Iida, Shinsuke and Morgan, Gareth and Suryanarayan, Kaveri and Teng, Zhaoyang and Skacel, Tomas and Palumbo, Antonio and Dash, Ajeeta B and Gupta, Neeraj and Labotka, Richard and Rajkumar, S Vincent and Bar, Daniel and Basso, Alfredo and Fantl, Dorotea and He, Simon and Horvath, Neomi and Lee, Cindy and Lee, Jae Hoon and Rowlings, Phillip and Taylor, Kerry and Cochrane, Tara and Kwok, Fiona and Ramanathan, Sundreswran and Agis, Hermine and Zojer, Niklas and Kentos, Alain and Offner, Fritz and Van Droogenbroeck, Jan and Wu, Ka Lung and Maiolino, Angelo and Martinez, Gracia and Zanella, Karla and Capra, Marcelo and Araújo, Sérgio and Gregora, Evzen and Pour, Ludek and Scudla, Vlastimil and Spicka, Ivan and Abildgaard, Niels and Andersen, Niels and Jensen, Bo Amdi and Helleberg, Carsten and Plesner, Torben and Salomo, Morten and Svirskaite, Asta and Delarue, Richard and Blau, Igor and Schieferdecker, Aneta and Teleanu, Veronica and Munder, Markus and Röllig, Christoph and Salwender, Han-Juergen and Fuhrmann, Stephan and Duerig, Jan and Zeis, Matthias and Klein, Stefan and Reimer, Peter and Schmidt, Christian and Scheid, Christof and Mayer, Karin and Hoffmann, Martin and Sosada, Markus and Delimpasi, Sosana and Kyrtsonis, Mary-Christine and Anagnostopoulos, Achilleas and Nagy, Zsolt and Illés, Árpád and Egyed, Miklós and Borbényi, Zita and Mikala, Gabor and Dally, Najib and Horowitz, Netanel and Gutwein, Odit and Nemets, Anatoly and Vaxman, Iuliana and Shvetz, Olga and Trestman, Svetlana and Ruchlemer, Rosa and Nagler, Arnon and Tadmor, Tamar and ... and TOURMALINE-MM3 Study Grp and TOURMALINE-MM3 study group
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10168, pp. 253 - 264
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 11, pp. 1055 - 1066
Journal Article
The Lancet Oncology, ISSN 1470-2045, 04/2017, Volume 18, Issue 4, pp. e206 - e217
The International Myeloma Working Group consensus aimed to provide recommendations for the optimal use of fluorodeoxyglucose ( F-FDG) PET/CT in patients with... 
Journal Article
best practice onkologie, ISSN 0946-4565, 10/2014, Volume 9, Issue 5, pp. 6 - 15
Journal Article